Safety of Chloroquine or Hydroxychloroquine Plus Azithromycin for the Treatment of COVID-19 Patients in Burkina Faso: An Observational Prospective Cohort Study

Rouamba, Toussaint; Barry, Houreratou; Ouédraogo, Espérance; Tahita, Marc Christian; Yaméogo, Nobila Valentin; Poda, Armel; Diendéré, Arnaud Eric; Ouédraogo, Abdoul–Salam; Valéa, Innocent; Koné, Amariane M; Thiombiano, Cherileila; Traoré, Isidore; Tarnagda, Zékiba; Sawadogo, Serge A; Gansane, Zakaria; Kambiré, Yibar; Sanou, Idrissa; Barro-Traoré, F.; Drabo, Maxime; Tinto, Halidou

doi:10.2147/tcrm.s330813

Cited by 9 publications

(4 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Azithromycin, an antibiotic widely used in Burkina Faso for Covid19 patient treatment (27,28), was inactive for 68.69% of E. coli isolates and for 35.59% of K. pneumoniae isolates (Table 4)…”

Section: Resistance To Antibioticsmentioning

confidence: 99%

Title: Healthcare center wastewaters in Burkina Faso: sources of ESBL, AmpC-β-lactamase and carbapenemase producing Escherichia coli and Klebsiella pneumoniae

Garba¹,

Bonkoungou²,

Millogo

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Background Extended-spectrum β-lactamase (ESBL), plasmid-mediated AmpC-β-lactamase and carbapenemase producing Escherichia coli and Klebsiella pneumoniae have spread into environment worldwide posing a possible public health threat. However, the prevalence data in low- and middle-income countries are still scarce. The aim of this study was to assess the occurrence of ESBL, AmpC-β-lactamase and carbapenemase producing and multidrug-resistant E. coli and K. pneumoniae in wastewater collected from healthcare centers in Burkina Faso. Methodology Eighty-four (84) wastewater samples were collected from 5 healthcare centers and bacterial counts on ESBL ChromAgar were performed. E. coli and K. pneumoniae isolates were identified using API20E. ESBL production was confirmed using the double disc synergy test (DDST). AmpC-β-lactamase detection was performed on Muller Hinton (MH) agar supplemented with cloxacillin (4µg/l). Carbapenemase testing was carried out using O.K.N.V.I. RESIST-5 immunochromatography test. Result E. coli and/ or K. pneumoniae strains were isolated from 82 wastewater samples (97.6%). In total, 170 strains were isolated, E. coli more commonly (64%). Average concentrations of ESBL producing bacteria per hospital varied from 1.10x105 to 5.23x106 CFU/ml. Out of 170 presumptive ESBL producing isolates and 51 presumptive AmpC-β-lactamase producing isolates, 95% and 45% were confirmed, respectively. Carbapenemase production was detected in 10 isolates, 6 were NDM producers, 3 were OXA-48 producers and 1 was NDM and OXA-48 producer. All isolates were multidrug resistant and, furthermore, all of them were resistant to all β-lactams tested. Also, resistance to ESBL inhibitors was common, up to 66% E. coli and 62% in K. pneumoniae. Amikacin, fosfomycin and nitrofurantoin were the antibiotics for which least resistance was detected. Conclusion This study showed that wastewater from healthcare centers constitutes a reservoir of multidrug-resistant bacteria in Burkina Faso, including those capable of producing carbapenemases, which may disseminate into environment and further back to humans. Therefore, following the microbiological quality of the wastewaters released from healthcare centers is important to include in the future national AMR surveillance program.

show abstract

Section: Resistance To Antibioticsmentioning

confidence: 99%

Title: Healthcare center wastewaters in Burkina Faso: sources of ESBL, AmpC-β-lactamase and carbapenemase producing Escherichia coli and Klebsiella pneumoniae

Garba¹,

Bonkoungou²,

Millogo

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Testowano również m.in. antybiotyki (aztromycynę), leki przeciwmalaryczne (chlorochina i hydrochlorochina) [30]. W Polsce dwie terapie zakażeń SARS-CoV-2 zyskały popularność: pierwsza związana z lekiem stosownym w leczeniu stwardnienia rozsianego -amantadyną [31] oraz terapia z wykorzystanie osocza ozdrowieńców [32].…”

Section: Leczenie Zakażenia Sars-cov-2 Czy Mogą Nam Pomóc Rośliny?unclassified

Immunopathology and pulmonary complications associated with SARS-CoV-2 virus infection. Can plants help us?

Hajduk¹,

Bałan²,

Stelmasiak³

et al. 2022

View full text Add to dashboard Cite

W czasie trwania pandemii wirusa SARS-CoV-2, która rozpoczęła się w 2019 r., zaobserwowano, że zdecydowana większość ludzi ma łagodny obraz kliniczny lub przechodzi chorobę COVID-19 całkowicie bezobjawowo. Jednak około 10% osób zakażonych wirusem będzie miało ciężki, potencjalnie śmiertelny przebieg kliniczny związany z hiperzapaleniem, uszkodzeniem śródbłonka naczyń, zmianami zakrzepowymi i uszkodzeniem płuc. Do oceny prognostycznej i rokowniczej przebiegu COVID-19 konieczne jest poznanie mechanizmów immunologicznych indukowanych po infekcji. Znajomość immunopatologii zakażenia jest niezbędna dla opracowania skutecznej terapii immunomodulującej. W pracy opisano wybrane immunomodulatory pochodzenia roślinnego, które mogą wykazywać działanie prewencyjne i łagodzące objawy choroby COVID-19.

show abstract

“…The SARS-Cov-2 infection causes a range of cases ranging from mild with mild clinical symptoms without pneumonia to severe and often fatal (respiratory distress, hypoxia (SpO 2 ≤ 93%), abnormal blood gases) [3] [4].…”

Section: Introductionmentioning

confidence: 99%

Clinical Evaluation of the Safety and Efficacy of the Phytomedicine APIVIRINE Based on Aqueous Extracts of <i>Dichrostachys glomerata</i> (Forssk.). Chiov. (<i>D. cinerea</i>) in COVID-19 Patients without Signs of Severity

Ouédraogo¹,

Tarnagda²,

Ouédraogo³

et al. 2023

IJCM

View full text Add to dashboard Cite

Background: Since the appearance of the COVID-19 pandemic, several drugs have also been proposed for the treatment of the COVID-19, but the therapeutic effectiveness of those drugs is not satisfactory. This situation has led to the search for therapeutic solutions based on recipes from traditional medicine. Aims: This study aimed to evaluate the clinical safety, efficacy and tolerability of the phytomedicine APIVIRINE in patients with non-severe COVID-19. Methods: Patients were included following defined criteria and followed on an outpatient basis until recovery in accordance with national guidelines for the management of single cases of COVID-19 in Burkina Faso. Vital signs, anthropometric parameters as well as electrocardiographic, hematological and biochemical examinations were measured on D4, D7, D14 and D21. Adverse events were recorded during maintenance. Results: The present study included 45 patients. The clinical signs present at inclusion were mostly cough (44.44%), asthenia (42.22%), headache (40%), and anosmia (35.55%). Dyspnoea and chest pain were less represented in 05 (11.11%) and 06 (13.33%) patients. Cough, dyspnoea, chest pain, fever, sore throat, headache, and nasal obstruction present at inclusion disappeared before Day 4 of treatment. Anosmia and asthenia disappeared before Day 7. At the inclusion visit (Day 1), CRP, WBC, and blood glucose were abnormal in 15

show abstract

Safety of Chloroquine or Hydroxychloroquine Plus Azithromycin for the Treatment of COVID-19 Patients in Burkina Faso: An Observational Prospective Cohort Study

Cited by 9 publications

References 50 publications

Title: Healthcare center wastewaters in Burkina Faso: sources of ESBL, AmpC-β-lactamase and carbapenemase producing Escherichia coli and Klebsiella pneumoniae

Title: Healthcare center wastewaters in Burkina Faso: sources of ESBL, AmpC-β-lactamase and carbapenemase producing Escherichia coli and Klebsiella pneumoniae

Immunopathology and pulmonary complications associated with SARS-CoV-2 virus infection. Can plants help us?

Clinical Evaluation of the Safety and Efficacy of the Phytomedicine APIVIRINE Based on Aqueous Extracts of <i>Dichrostachys glomerata</i> (Forssk.). Chiov. (<i>D. cinerea</i>) in COVID-19 Patients without Signs of Severity

Contact Info

Product

Resources

About

Safety of Chloroquine or Hydroxychloroquine Plus Azithromycin for the Treatment of COVID-19 Patients in Burkina Faso: An Observational Prospective Cohort Study

Cited by 9 publications

References 50 publications

Title: Healthcare center wastewaters in Burkina Faso: sources of ESBL, AmpC-β-lactamase and carbapenemase producing Escherichia coli and Klebsiella pneumoniae

Title: Healthcare center wastewaters in Burkina Faso: sources of ESBL, AmpC-β-lactamase and carbapenemase producing Escherichia coli and Klebsiella pneumoniae

Immunopathology and pulmonary complications associated with SARS-CoV-2 virus infection. Can plants help us?

Clinical Evaluation of the Safety and Efficacy of the Phytomedicine APIVIRINE Based on Aqueous Extracts of &lt;i&gt;Dichrostachys glomerata&lt;/i&gt; (Forssk.). Chiov. (&lt;i&gt;D. cinerea&lt;/i&gt;) in COVID-19 Patients without Signs of Severity

Contact Info

Product

Resources

About

Clinical Evaluation of the Safety and Efficacy of the Phytomedicine APIVIRINE Based on Aqueous Extracts of <i>Dichrostachys glomerata</i> (Forssk.). Chiov. (<i>D. cinerea</i>) in COVID-19 Patients without Signs of Severity